Su 21 Casi Di Induratio Penis Plastica Trattati Con Orgoteina

Abstract

Get full access to this article

View all access options for this article.

References

Altaffer

L. F.

, Jordan

G. H.

: Sonographic demonstration of Peyronie's plaques. Urology, 17; 292 (1981).

Bartsch

, Mennader-Huber

K. B.

, Marberger

: Orgotein, a new drug for the treatment of Peyronie's disease. Eur. Rheum. Inflam., 4; 250 (1981).

Carson

C. C.

, Hodge

G. B.

, Anderson

E. E.

: Penile prosthesis in Peyronie's disease. Brit. J. Urol., 55; 417 (1983).

Chilton

C. P.

: Factors associated in the etiology of Peyronie's disease. Brit. J. Urol., 54; 748 (1982).

Das

, Amar

A. D.

: Peyronie's disease; exicision of the plaque and grafting with tunica vaginalis. Urol. Clin. N. Amer., 9; 197 (1982).

Fleischer

A. C.

, Rhamy

R. K.

: Sonographic evaluation of Peyronie's disease. Urology, 17; 290 (1981).

Godec

C. J.

, Van Beek

A. L.

: Peyronie's disease is curable, is it also preventable? Urloogy, 21; 257 (1983).

Gustafson

, Johansson

, Edsmyr

Folke

: Peyronie's disease: experience of local treatment with Orgotein. Eur. Urol., 7; 346–348 (1981).

Lowe

D. H.

: Surgical treatment of Peyronie's disease with dacron graft. Urology, 19; 609 (1982).

10.

Lund-Olsen

, Menander

K. B.

: Orgotein, a new anti-inflammatory metallo-protein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease. Curr. Therap. Res., 16; 706 (1974).

11.

Marberger

, Bartsch

, Huber

: Orgotein, a new drug for the treatment of radiation cistitis. Curr. Ther. Res., 19; 198–211 (1976).

12.

Marberger

, Huber

W. G.

: Orgotein a new antiflammatory metalloprotein drug. Evaluation of clinical efficacy and satefy in inflammatory conditions of the urinary tract. Intern. Urol. & Nephrol., 6; 61–62 (1974).

13.

Van De

Berg R.

: Peyronie's disease: electron microscopic study. J. Urol., 126; 333 (1981).

14.

Williams

, Green

N. A.

: The non-surgical treatment of Peyronie's disease. Brit. J. Urol., 52; 392 (1980).